21 CFR 529.400
§ 529.400 Chlorhexidine tablets and suspension.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 529.400, § 529.400 Chlorhexidine tablets and suspension, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87683
- Permanent ID
ys:prov:87683@1- SHA-256
a0a8524eb6173e36fdc9d06f3be0b364eb1ab861edc0d6e9f661be2c0f7a8d20
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specification. Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.120 of this chapter.
(d) Conditions of use—(1) Amount. Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet disolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.
(2) Indications for use. For prevention or treatment of metritis and vaginitis in cows and mares when caused by pathogens sensitive to chlorhexidine dihydrochloride.
(3) Limitations. Prior to administration, remove any unattached placental membranes, any excess uterine fluid or debris, and carefully clean external genitalia. Use a clean, sterile inseminating pipette for administrating solutions and suspensions. Treatment may be repeated in 48 to 72 hours.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.